Synageva's LAL deficiency drug wins breakthrough designation from FDA

05/21/2013 | American City Business Journals

The FDA granted breakthrough therapy status to Synageva BioPharma's experimental drug sebelipase alfa, or SBC-102, as a treatment for early onset lysosomal acid lipase deficiency, also known as Wolman disease. The drug is currently in clinical trials against both early onset and late onset LAL deficiency. Sebelipase alfa previously won orphan designation and fast track status from the FDA.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA